Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
Go

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$2.25
Day's Change
-0.2236 (-9.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.31
Day's Low
2.16
Volume
(Heavy Day)

Today's volume of 168,452 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.

168,452

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freshworks Inc. - FRSH

4:58 pm ET January 1, 2023 (Globe Newswire) Print
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Freshworks Inc. - FRSHGlobeNewswireJanuary 01, 2023

NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Freshworks Inc. ("Freshworks" or the "Company") (NASDAQ: FRSH). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Freshworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On or around September 22, 2021, Freshworks conducted its initial public offering ("IPO"), offering 28.5 million shares of its common stock to the investing public at a price of $36 per share (the "Offering Price"). According to the IPO's offering documents (the "Offering Documents"), Freshworks' business had "grown rapidly" in the lead up to the IPO and the Company observed "broad appeal of [its] products to customers of all sizes and geographies." Consequently, the Company's growth rates and purportedly "healthy" net dollar retention rates reached levels not previously achieved, and there was no indication that either was decelerating. However, the Offering Documents failed to disclose that at the time of the IPO, Freshworks' revenue growth and billings had encountered significant obstacles. As the truth about Freshworks' business and operations came to light after the IPO, the Company's share price fell sharply, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980



comtex tracking

COMTEX_421732019/2010/2023-01-01T16:58:40

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.